These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1120 related items for PubMed ID: 25494701

  • 1. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y, Herrstedt J, Havsteen H, DePoint Christensen R, Mirza MR, Lund B, Maenpaa J, Kristensen G.
    BMC Cancer; 2014 Dec 11; 14():937. PubMed ID: 25494701
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
    Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL.
    Gynecol Oncol; 2013 Jun 11; 129(3):452-8. PubMed ID: 23474348
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Nakanishi T, Aoki D, Watanabe Y, Ando Y, Tomotsugu N, Sato Y, Saito T.
    Jpn J Clin Oncol; 2015 May 11; 45(5):422-6. PubMed ID: 25670764
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of docetaxel weekly in combination with carboplatin every 3 weeks as first-line chemotherapy in stage IIB to stage IV epithelial ovarian cancer.
    Sorbe B, Graflund M, Horvath G, Swahn M, Boman K, Bangshöj R, Lood M, Malmström H.
    Int J Gynecol Cancer; 2012 Jan 11; 22(1):47-53. PubMed ID: 22193643
    [Abstract] [Full Text] [Related]

  • 8. A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation.
    Sorbe B, Graflund M, Nygren L, Horvath G, Swahn M, Boman K, Bangshöj R, Lood M, Malmström H.
    Int J Oncol; 2012 Mar 11; 40(3):773-81. PubMed ID: 22159569
    [Abstract] [Full Text] [Related]

  • 9. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
    Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, Scottish Gynaecological Cancer Trials Group.
    J Natl Cancer Inst; 2004 Nov 17; 96(22):1682-91. PubMed ID: 15547181
    [Abstract] [Full Text] [Related]

  • 10. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
    Abaid LN, Micha JP, Rettenmaier MA, Brown JV, Mendivil AA, Lopez KL, Goldstein BH.
    Cancer Chemother Pharmacol; 2013 Jul 17; 72(1):101-7. PubMed ID: 23660691
    [Abstract] [Full Text] [Related]

  • 11. Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
    Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J.
    J Clin Oncol; 2001 Apr 01; 19(7):1901-5. PubMed ID: 11283121
    [Abstract] [Full Text] [Related]

  • 12. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
    Schwandt A, von Gruenigen VE, Wenham RM, Frasure H, Eaton S, Fusco N, Fu P, Wright JJ, Dowlati A, Waggoner S.
    Invest New Drugs; 2014 Aug 01; 32(4):729-38. PubMed ID: 24619298
    [Abstract] [Full Text] [Related]

  • 13. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Gould N, Sill MW, Mannel RS, Thaker PH, DiSilvestro PA, Waggoner SE, Yamada SD, Armstrong DK, Fracasso PM, Walker JL.
    Gynecol Oncol; 2012 Dec 01; 127(3):506-10. PubMed ID: 22943879
    [Abstract] [Full Text] [Related]

  • 14. Second-line chemotherapy with docetaxel and carboplatin in paclitaxel and platinum-pretreated ovarian, fallopian tube, and peritoneal cancer.
    Arimoto T, Nakagawa S, Oda K, Kawana K, Yasugi T, Taketani Y.
    Med Oncol; 2012 Jun 01; 29(2):1253-4. PubMed ID: 21380784
    [Abstract] [Full Text] [Related]

  • 15. A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
    Reyners AKL, de Munck L, Erdkamp FLG, Smit WM, Hoekman K, Lalisang RI, de Graaf H, Wymenga ANM, Polee M, Hollema H, van Vugt MATM, Schaapveld M, Willemse PHB, DoCaCel Study Group.
    Ann Oncol; 2012 Nov 01; 23(11):2896-2902. PubMed ID: 22689176
    [Abstract] [Full Text] [Related]

  • 16. Health-related quality of life outcomes of docetaxel/carboplatin combination therapy vs. sequential therapy with docetaxel then carboplatin in patients with relapsed, platinum-sensitive ovarian cancer: results from a randomized clinical trial.
    Pokrzywinski R, Secord AA, Havrilesky LJ, Puls LE, Holloway RW, Lewandowski GS, Higgins RV, Nycum LR, Kohler MF, Revicki DA.
    Gynecol Oncol; 2011 Dec 01; 123(3):505-10. PubMed ID: 21945310
    [Abstract] [Full Text] [Related]

  • 17. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
    Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, Aoki D, Jobo T, Kodama S, Terauchi F, Sugiyama T, Ochiai K, Japanese Gynecologic Oncology Group.
    Lancet Oncol; 2013 Sep 01; 14(10):1020-6. PubMed ID: 23948349
    [Abstract] [Full Text] [Related]

  • 18. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
    Herzog TJ, Monk BJ, Rose PG, Braly P, Hines JF, Bell MC, Wenham RM, Secord AA, Roman LD, Einstein MH, Drake RD, Childs BH.
    Gynecol Oncol; 2014 Mar 01; 132(3):517-25. PubMed ID: 24476788
    [Abstract] [Full Text] [Related]

  • 19. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
    Nagao S, Iwasa N, Kurosaki A, Nishikawa T, Ohishi R, Hasegawa K, Goto T, Fujiwara K.
    Int J Gynecol Cancer; 2012 Jan 01; 22(1):70-5. PubMed ID: 22146766
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.